<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Patient Prefer Adherence</journal-id><journal-id journal-id-type="iso-abbrev">Patient Prefer Adherence</journal-id><journal-id journal-id-type="publisher-id">Patient Preference and Adherence</journal-id><journal-title-group><journal-title>Patient preference and adherence</journal-title></journal-title-group><issn pub-type="epub">1177-889X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28280310</article-id><article-id pub-id-type="pmc">5338963</article-id><article-id pub-id-type="doi">10.2147/PPA.S127997</article-id><article-id pub-id-type="publisher-id">ppa-11-373</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Impact of late-to-refill reminder calls on medication adherence in the Medicare Part D population: evaluation of a randomized controlled study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Taitel</surname><given-names>Michael S</given-names></name><xref ref-type="aff" rid="af1-ppa-11-373"/><xref ref-type="corresp" rid="c1-ppa-11-373"/></contrib><contrib contrib-type="author"><name><surname>Mu</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="af1-ppa-11-373"/></contrib><contrib contrib-type="author"><name><surname>Gooptu</surname><given-names>Angshuman</given-names></name><xref ref-type="aff" rid="af1-ppa-11-373"/></contrib><contrib contrib-type="author"><name><surname>Lou</surname><given-names>Youbei</given-names></name><xref ref-type="aff" rid="af1-ppa-11-373"/></contrib></contrib-group><aff id="af1-ppa-11-373">Health Analytics, Research &#x00026; Reporting, Walgreen Co., Deerfield, IL, USA</aff><author-notes><corresp id="c1-ppa-11-373">Correspondence: Michael S Taitel, Health Analytics, Research &#x00026; Reporting, Walgreen Co., 1415 Lake Cook Road, 4th Floor, Deerfield, IL 60015-5213, USA, Tel +1 847 964 8102, Fax +1 847 374 2669, Email <email>michael.taitel@walgreens.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>28</day><month>2</month><year>2017</year></pub-date><volume>11</volume><fpage>373</fpage><lpage>379</lpage><permissions><copyright-statement>&#x000a9; 2017 Taitel et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2017</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Objectives</title><p>This study evaluates a nationwide pharmacy chain&#x02019;s late-to-refill (LTR) reminder program that entails local pharmacists placing reminder calls to Medicare Part D patients.</p></sec><sec><title>Methods</title><p>We conducted a randomized controlled study among 735,218 patients who exhibited nonadherent behavior by not refilling a maintenance medication 3 days from an expected refill date. Patients were randomly assigned to an intervention group who received LTR reminder calls or to a control group. We used Walgreens pharmaceutical claims data from 2015 to estimate the impact of LTR calls on short-term and annual adherence.</p></sec><sec><title>Results</title><p>The initial refill rate within the first 14 days of the expected refill date significantly increased in the intervention group by 22.8% (6.09 percentage points) compared to the control group (<italic>P</italic>&#x0003c;0.001). The proportion of days covered (PDC) in the intervention group increased significantly by 1.5% (0.856 percentage points) relative to the control group (<italic>P</italic>&#x0003c;0.001) over 365 days. Patients in the intervention group were significantly more adherent (PDC &#x02265;80%) by 3% (0.97 percentage points) compared to the control group (<italic>P</italic>&#x0003c;0.001). Over a 270-day follow-up period, persistence significantly increased by 2.15 days in the intervention group (<italic>P</italic>&#x0003c;0.001).</p></sec><sec><title>Conclusion</title><p>Results from this study suggest that LTR reminder calls increased adherence for Medicare Part D patients who are late in refilling their medications and therefore have the potential to reduce their risk for hospitalization and health care costs. Additionally, the intervention increased the number of patients with PDC &#x02265;80% by ~3%, positively impacting Medicare Part D plan quality rating.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>reminder system</kwd><kwd>tailored intervention</kwd><kwd>Medicare Part D</kwd><kwd>adherence</kwd><kwd>persistence</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Maintenance medications are drugs prescribed to patients over a long period of time in order to treat chronic conditions such as diabetes, hypertension, heart disease, and depression.<xref rid="b1-ppa-11-373" ref-type="bibr">1</xref> However, when researchers study patients&#x02019; use of maintenance medications over time, they note that within the first 6 months a significant number of patients in the US become nonadherent to their prescribed treatment.<xref rid="b2-ppa-11-373" ref-type="bibr">2</xref> The World Health Organization (WHO) estimates that the average rate of nonadherence among patients in the US with one or more chronic conditions is ~50%.<xref rid="b1-ppa-11-373" ref-type="bibr">1</xref> Furthermore, patients with multiple chronic conditions are more likely to be nonadherent.<xref rid="b3-ppa-11-373" ref-type="bibr">3</xref></p><p>Increasing adherence to maintenance medications benefits both patients and the health care system. First, adherent patients experience a reduction in mortality risks.<xref rid="b4-ppa-11-373" ref-type="bibr">4</xref> Second, they are less likely to be hospitalized and use the emergency room and are therefore protected from unexpected health care cost.<xref rid="b5-ppa-11-373" ref-type="bibr">5</xref>&#x02013;<xref rid="b8-ppa-11-373" ref-type="bibr">8</xref> Third, with an increasingly adherent patient population, the health care system becomes more cost-efficient.<xref rid="b3-ppa-11-373" ref-type="bibr">3</xref>,<xref rid="b5-ppa-11-373" ref-type="bibr">5</xref>,<xref rid="b9-ppa-11-373" ref-type="bibr">9</xref></p><p>Patients become nonadherent to their medication regimen due to a complex set of observable and unobservable dimensions,<xref rid="b6-ppa-11-373" ref-type="bibr">6</xref>,<xref rid="b8-ppa-11-373" ref-type="bibr">8</xref> including those related to the health care system,<xref rid="b10-ppa-11-373" ref-type="bibr">10</xref>&#x02013;<xref rid="b12-ppa-11-373" ref-type="bibr">12</xref> the specific medication therapy,<xref rid="b12-ppa-11-373" ref-type="bibr">12</xref> the chronic condition,<xref rid="b13-ppa-11-373" ref-type="bibr">13</xref> and patients&#x02019; unique psychological and cognitive factors.<xref rid="b14-ppa-11-373" ref-type="bibr">14</xref></p><p>Medicare beneficiaries, comprised of the elderly (aged &#x02265;65 years) and the disabled, obtain comprehensive drug coverage from privately covered prescription drug plans &#x02013; Medicare Part D plans.<xref rid="b15-ppa-11-373" ref-type="bibr">15</xref>&#x02013;<xref rid="b17-ppa-11-373" ref-type="bibr">17</xref> However, even though Medicare Part D beneficiaries pay a lower cost for maintenance medications, many are still nonadherent.<xref rid="b18-ppa-11-373" ref-type="bibr">18</xref> Forgetfulness<xref rid="b18-ppa-11-373" ref-type="bibr">18</xref> and concerns about medication effectiveness and side effects<xref rid="b19-ppa-11-373" ref-type="bibr">19</xref> are the primary reasons for nonadherence in this patient population.</p><p>We focus on adherence in the Medicare Part D patient population since an incremental improvement in the adherence level of these patients can, in turn, not only reduce the risk of hospitalization and unexpected medical spending for patients but also increase the star quality rating of Medicare Part D plans. In particular, the star rating computation heavily weighs patient adherence to antidiabetic, antihypertensive, and antihyperlipidemic medications.<xref rid="b16-ppa-11-373" ref-type="bibr">16</xref> A higher star rating &#x02013; annually assigned by the Centers for Medicare and Medicaid Services (CMS)<xref rid="b16-ppa-11-373" ref-type="bibr">16</xref> &#x02013; increases the potential profitability of individual Medicare Part D plans with higher payments from the CMS<xref rid="b16-ppa-11-373" ref-type="bibr">16</xref>,<xref rid="b17-ppa-11-373" ref-type="bibr">17</xref> and increased beneficiary enrollment throughout the year.<xref rid="b20-ppa-11-373" ref-type="bibr">20</xref>,<xref rid="b21-ppa-11-373" ref-type="bibr">21</xref></p><p>Since pharmacists and pharmacy staff frequently interact with their patients and establish strong pharmacist-to-patient relationships, they are uniquely positioned to address their patient&#x02019;s medication concerns and help improve adherence.<xref rid="b22-ppa-11-373" ref-type="bibr">22</xref>,<xref rid="b23-ppa-11-373" ref-type="bibr">23</xref> Moreover, while physicians play a significant role counseling their patients on adherence to medications, they are often ill-equipped in identifying nonadherence.<xref rid="b22-ppa-11-373" ref-type="bibr">22</xref>,<xref rid="b23-ppa-11-373" ref-type="bibr">23</xref> In contrast, pharmacies have access to prescription refill information, which is a reliable source of data to identify nonadherence.</p><p>In fact, pharmacies have implemented tailored interventions to improve adherence among their patients with chronic conditions.<xref rid="b24-ppa-11-373" ref-type="bibr">24</xref>,<xref rid="b25-ppa-11-373" ref-type="bibr">25</xref> To address forgetfulness, some pharmacies offer omnichannel (pharmacy telephone calls, automated calls, emails, text messages, etc) refill reminders that include automated refill reminders, pickup reminders, and late-to-refill (LTR) reminders.<xref rid="b6-ppa-11-373" ref-type="bibr">6</xref></p><p>This study evaluates the efficacy of a nationwide pharmacy chain&#x02019;s LTR reminder program, which entails local pharmacists placing reminder calls to Medicare Part D patients who are late in refilling their maintenance medication(s) on patient&#x02019;s adherence and persistence to medication. We hypothesize that LTR calls placed by pharmacists will significantly increase medication adherence among Medicare Part D patients.</p></sec><sec sec-type="methods"><title>Methods</title><p>We conducted a randomized controlled study to measure the impact of the LTR reminder calls on adherence. This study, including a waiver of consent, was approved by Quorum Institutional Review Board Protocol # 29081.</p><sec sec-type="methods"><title>Data sources and patient election</title><p>Study participants included all Walgreens Medicare Part D patients in the US who were 3 days late in refilling their maintenance medication between January 1, 2015, and January 31, 2015. We collected their pharmacy claims data from July 2014 through January 2016. Participants were randomly assigned to receive the LTR reminder call intervention or to a usual care control group (ie, no reminder calls).</p></sec><sec><title>Intervention</title><p>Pharmacists conducted LTR calls from more than 8,000 Walgreens&#x02019; locations in communities across the US. During the call, pharmacists reminded patients that they are late for a refill and offered to refill their prescription. Pharmacists also asked patients about their barriers to adherence and informed them about various programs to support their adherence such as email and text refill reminders, smartphone apps, script alignment, and 90-day prescriptions. If patients were overdue for multiple maintenance medication refills, they were reminded of all medication refills due during one phone call. Each time a patient was late for a refill, pharmacists made a total of three attempts to reach the patient by phone over a 3-day period. Control patients became eligible to receive LTR calls from April 2016. Patients were not excluded if they were eligible or participating in other pharmacy intervention programs. On average, patients were late to refill their maintenance medications ~2.3 times during the study period.</p></sec><sec><title>Outcomes assessment</title><p>We measured adherence outcomes within a month of the expected refill date and after 1 year. To assess the short-term impact of the program, we calculated the refill rate as the percentage of prescriptions refilled within 7, 14, and 30 days after the expected refill date.</p><p>To evaluate the 1-year adherence, we calculated three outcome measures: 1) the proportion of days covered (PDC) as a continuous measure, 2) the PDC as a categorical measure, and 3) persistence.</p><p>PDC measures are defined at the drug class level using the Generic Product Identifier (GPI) six-digit level from a standard hierarchical drug classification system &#x02013; the Medi-Span&#x02122; Master Drug Database (Wolters Kluwer Health Inc, Conshohocken, PA, USA). The GPI is a 14-digit code that helps identify pharmaceutical drugs with the same active ingredients, dosage, and strength.<xref rid="b26-ppa-11-373" ref-type="bibr">26</xref> The first six digits (GPI-6) of the GPI combine pharmaceutically equivalent drugs together at the therapeutic subclass level.<xref rid="b26-ppa-11-373" ref-type="bibr">26</xref></p><p>We defined the PDC as the number of days patients were in possession of their medication over 365 days from the index date. The index date is the sold date for the prescription that triggered the LTR reminder call in January 2015.</p><p>The continuous PDC measure can range from nearly 0% to 100%; the greater the value, the better the adherence. The categorized PDC measure distinguishes patients who are nonadherent (PDC &#x0003c;50%), partially adherent (50% &#x02264; PDC &#x0003c;80%), and adherent (PDC &#x02265;80%). The PDC thresholds used to classify patients closely follow the thresholds used by previous adherence studies.<xref rid="b10-ppa-11-373" ref-type="bibr">10</xref>,<xref rid="b27-ppa-11-373" ref-type="bibr">27</xref>,<xref rid="b28-ppa-11-373" ref-type="bibr">28</xref></p><p>Persistence is measured as the duration of days from initiation to discontinuation of maintenance medication over a 270-day period. Discontinuation is defined as a failure to refill medications within 90 days of the expected refill date.</p><p>We compared differences in the outcome measures between the intervention and control groups. Student&#x02019;s <italic>t</italic>-tests were used to evaluate significant differences in continuous PDC and persistence. Chi-squared tests were used to assess the statistical significance of the differences in refill rates and the share of patients within specific PDC categories (adherent, partially adherent, and nonadherent). All data analyses were performed with SAS 9.3 software (SAS Institute Inc., Cary, NC, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><p>Across the 1-year study period, 735,218 Medicare Part D patients who were 3 days overdue were placed on a contact list for LTR reminder calls. Of these patients, 367,631 were randomly assigned to the intervention group and 367,587 were randomly assigned to the control group.</p><p>Results in <xref ref-type="table" rid="t1-ppa-11-373">Table 1</xref> display the baseline characteristics of patients in the intervention and control groups. Baseline patient characteristics in both groups were similar. For instance, more than 60% of the patients were female, ~70 years of age, and took ~4 medications over a 6-month period. There were also no significant differences in comorbidities between patients in the two groups at baseline since a majority of the medications purchased by both groups were similar. Since the observable baseline demographic and health characteristics are not significantly different, these results validate that randomization was achieved.</p><p>Trends in <xref ref-type="fig" rid="f1-ppa-11-373">Figure 1</xref> and <xref ref-type="table" rid="t2-ppa-11-373">Table 2</xref> show that the cumulative refill rate was significantly higher in the intervention group by an average of 3.8 percentage points within the first 7 days and 6.1 percentage points within the first 14 days after the expected refill date (<italic>P</italic>&#x0003c;0.001). The cumulative refill rate was significantly higher in the intervention group by an average of 4.4 percentage points within the first 30 days after the expected refill date (<italic>P</italic>&#x0003c;0.001).</p><p>Furthermore, comparing the cumulative refill rates over a 30-day follow-up period between the intervention and control groups by their top 10 therapeutic classes shows that the LTR reminder calls significantly increased refill rates across all therapeutic classes ranging from 3.4 to 5.2 percentage points (<italic>P</italic>&#x0003c;0.001; <xref ref-type="table" rid="t3-ppa-11-373">Table 3</xref>).</p><sec><title>PDC and persistence</title><p>Results in <xref ref-type="table" rid="t4-ppa-11-373">Table 4</xref> illustrate that the mean PDC in the intervention group significantly increased by 0.9 percentage points relative to the control group (<italic>P</italic>&#x0003c;0.001). Furthermore, results in <xref ref-type="table" rid="t5-ppa-11-373">Table 5</xref> confirm the number of nonadherent patients (PDC &#x0003c;50%) in the intervention group was significantly lower than the control group by 1.1 percentage points (<italic>P</italic>&#x0003c;0.001). In contrast, the number of adherent patients (PDC &#x02265;80%) in the intervention group was significantly greater than the control group by 1.0 percentage points (<italic>P</italic>&#x0003c;0.001).</p><p>Persistence in a 270-day follow-up period with a 90-day discontinuation gap in the intervention group was significantly (<italic>P</italic>&#x0003c;0.001) higher than that in the control group by 2.2 days (<xref ref-type="table" rid="t6-ppa-11-373">Table 6</xref>). Since the optimal discontinuous gap period may vary in accordance to clinical relevance and there is no consensus on the average permissible gap period in the literature,<xref rid="b29-ppa-11-373" ref-type="bibr">29</xref> we tested if results changed using a 120-day discontinuation gap period. We found that the average persistency difference between intervention and control group patients was robust and did not change.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Approximately 32% of Medicare Part D patients are nonadherent to their diabetes, hypertension, and cholesterol medications.<xref rid="b30-ppa-11-373" ref-type="bibr">30</xref> Patient forgetfulness and misconceptions about the risk of side effects are potential drivers of nonadherence in this population.<xref rid="b31-ppa-11-373" ref-type="bibr">31</xref>,<xref rid="b32-ppa-11-373" ref-type="bibr">32</xref> Local pharmacists can nudge patients to increase adherence since they can remind them to refill medications on time and address their concerns about their medications.<xref rid="b18-ppa-11-373" ref-type="bibr">18</xref>,<xref rid="b19-ppa-11-373" ref-type="bibr">19</xref>,<xref rid="b22-ppa-11-373" ref-type="bibr">22</xref>,<xref rid="b23-ppa-11-373" ref-type="bibr">23</xref>,<xref rid="b32-ppa-11-373" ref-type="bibr">32</xref></p><p>We conducted a randomized study of an LTR medication reminder program within the Medicare Part D population. Using pharmacy claims data, we evaluated each patient&#x02019;s medication utilization over 1 year. Results confirmed that in the Medicare Part D population, LTR reminder calls from local pharmacists significantly increased the cumulative refill rate of their maintenance medications across a variety of therapeutic classes by an average of 22.8% (6.09 percentage points) within the first 14 days after being due for a refill. LTR reminder calls increased average PDC by 1.5% (0.856 percentage points) over a 1 year period and persistence by 2.2 days over a period of 270 days. The results suggest that sustained reminder calls placed by the local pharmacist to Medicare Part D patients, who are late for refills, can improve refill rates in the short term and lead to increased adherence and persistence in the long term.</p><p>Adherence measured by PDC tends to be higher in the Medicare Part D population than in the commercial insurance population.<xref rid="b33-ppa-11-373" ref-type="bibr">33</xref> However, since this study included only Medicare Part D patients who were already late for a refill, the PDC of the study cohort is lower than the average PDC that we generally observe in the Medicare Part D population.</p><p>Previous studies have evaluated the impact of innovative pharmacy programs at increasing adherence and found encouraging results.<xref rid="b6-ppa-11-373" ref-type="bibr">6</xref>,<xref rid="b24-ppa-11-373" ref-type="bibr">24</xref>,<xref rid="b32-ppa-11-373" ref-type="bibr">32</xref> However, a number of these studies evaluated the impact of a multifaceted set of interventions on adherence. Patients in both intervention and control groups in our study may have received a variety of pharmacy interventions. We focused on the impact of the pharmacist LTR reminder calls on adherence. In addition, the robustness of the findings reported in the literature is relatively weak since a majority of the studies were observational. In comparison, our results are based on a randomized controlled study allowing us to conclude with confidence that increased adherence was attributable to the intervention and not unobserved factors.<xref rid="b34-ppa-11-373" ref-type="bibr">34</xref> Furthermore, given the broad geographic footprint of Walgreens, participants in the present study were representative of the US population. Across the US, there are larger regional variations in adherence among patients in Medicare Part D plans relative to patients in commercial insurance plans,<xref rid="b33-ppa-11-373" ref-type="bibr">33</xref> but most of the previous studies are not representative of the US Medicare population and have therefore been unable to control for this variability.</p><p>Still, our study has some limitations. First, we are unable to distinguish patients who are nonadherent to their medications from those who switched pharmacies, switched plans, dropped out of Medicare Part D, or died. Second, we are unable to assess the long-term impact of LTR reminder calls on the intervention population beyond 1 year. Third, our study focuses on Medicare Part D patients and may not generalize other patient populations.</p><p>Nonetheless, our findings are relevant for Medicare Part D insurance plans. Our study shows that for Medicare Part D patients who exhibited nonadherent behavior &#x02013; not refilling at least 3 days from the expected January refill date &#x02013; an LTR reminder call increased the number of adherent patients (PDC &#x02265;80%) by ~3% (0.97 percentage points). This incremental improvement in patient adherence can have significant implications on Medicare Part D plans, the star rating, and their associated financial impact. Consequently, the LTR reminder call intervention has the potential to improve the star ratings of Medicare Part D plans.</p></sec><sec><title>Conclusion</title><p>Using a randomized controlled study, we demonstrated that refill reminder calls from a local pharmacist to patients who were 3 days late in refilling their maintenance medication significantly improved adherence in the Medicare Part D patient population. Patients who received the intervention were 1) more likely to refill their medication within the first 14 days of their expected refill date, 2) more likely to have a higher adherence (PDC) throughout a period of 365 days, and 3) more likely to persist on their medication. Within the targeted population, the intervention significantly increased the number of adherent Medicare Part D patients (PDC &#x02265;80%) by ~3% (0.97 percentage points), including the drug classes (antidiabetics, antihypertensives, and antihyperlipidemics) that impact the CMS star rating.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Kara Clark, FSA, MAAA (Walgreen Co.), Catherine MacPherson, MS, RD (Walgreen Co.), Renae Smith-Ray, PhD (Walgreen Co.), and Junjie Zhang, FSA, MAAA (Walgreen Co.) for their review of the manuscript and helpful comments and insights.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>All the authors are employees of Walgreen Co. The authors report no other conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ppa-11-373"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chisholm-Burns</surname><given-names>MA</given-names></name><name><surname>Spivey</surname><given-names>CA</given-names></name></person-group><article-title>The &#x02018;cost&#x02019; of medication nonadherence: consequences we cannot afford to accept</article-title><source>J Am Pharm Assoc (2003)</source><year>2012</year><volume>52</volume><issue>6</issue><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">23229971</pub-id></element-citation></ref><ref id="b2-ppa-11-373"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sabat&#x000e9;</surname><given-names>E</given-names></name></person-group><source>Adherence to Long-term Therapies: Evidence for Action</source><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>World Health Organization</publisher-name><year>2003</year></element-citation></ref><ref id="b3-ppa-11-373"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>A</given-names></name></person-group><source>Issue Brief: Medication Adherence and Health IT</source><publisher-loc>Washington DC</publisher-loc><publisher-name>Department of Health and Human Services</publisher-name><year>2014</year></element-citation></ref><ref id="b4-ppa-11-373"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>PM</given-names></name><name><surname>Magid</surname><given-names>DJ</given-names></name><name><surname>Masoudi</surname><given-names>FA</given-names></name><name><surname>McClure</surname><given-names>DL</given-names></name><name><surname>Rumsfeld</surname><given-names>JS</given-names></name></person-group><article-title>Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease</article-title><source>BMC Cardiovasc Disord</source><year>2006</year><volume>6</volume><fpage>48</fpage><pub-id pub-id-type="pmid">17173679</pub-id></element-citation></ref><ref id="b5-ppa-11-373"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittman</surname><given-names>DG</given-names></name><name><surname>Tao</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Stettin</surname><given-names>GD</given-names></name></person-group><article-title>Antihypertensive medication adherence and subsequent healthcare utilization and costs</article-title><source>Am J Manag Care</source><year>2010</year><volume>16</volume><issue>8</issue><fpage>568</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">20712390</pub-id></element-citation></ref><ref id="b6-ppa-11-373"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akinbosoye</surname><given-names>OE</given-names></name><name><surname>Taitel</surname><given-names>MS</given-names></name><name><surname>Grana</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name><name><surname>Wade</surname><given-names>RL</given-names></name></person-group><article-title>Improving medication adherence and health care outcomes in a commercial population through a community pharmacy</article-title><source>Popul Health Manag</source><year>2016</year><volume>19</volume><issue>6</issue><fpage>454</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">27035728</pub-id></element-citation></ref><ref id="b7-ppa-11-373"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roebuck</surname><given-names>MC</given-names></name><name><surname>Liberman</surname><given-names>JN</given-names></name><name><surname>Gemmill-Toyama</surname><given-names>M</given-names></name><name><surname>Brennan</surname><given-names>TA</given-names></name></person-group><article-title>Medication adherence leads to lower health care use and costs despite increased drug spending</article-title><source>Health Aff (Millwood)</source><year>2011</year><volume>30</volume><issue>1</issue><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">21209444</pub-id></element-citation></ref><ref id="b8-ppa-11-373"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kymes</surname><given-names>SM</given-names></name><name><surname>Pierce</surname><given-names>RL</given-names></name><name><surname>Girdish</surname><given-names>C</given-names></name><name><surname>Matlin</surname><given-names>OS</given-names></name><name><surname>Brennan</surname><given-names>T</given-names></name><name><surname>Shrank</surname><given-names>WH</given-names></name></person-group><article-title>Association among change in medical costs, level of comorbidity, and change in adherence behavior</article-title><source>Am J Manag Care</source><year>2016</year><volume>22</volume><issue>8</issue><fpage>e295</fpage><lpage>e301</lpage><pub-id pub-id-type="pmid">27556832</pub-id></element-citation></ref><ref id="b9-ppa-11-373"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Braithwaite</surname><given-names>S</given-names></name><name><surname>Shirkhorshidian</surname><given-names>I</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Johnsrud</surname><given-names>M</given-names></name></person-group><source>The Role of Medication Adherence in the US Healthcare System</source><publisher-name>Washington, DC</publisher-name><publisher-name>Alvalere Health LLC</publisher-name><year>2013</year></element-citation></ref><ref id="b10-ppa-11-373"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhry</surname><given-names>NK</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><name><surname>Avorn</surname><given-names>J</given-names></name><etal/></person-group><article-title>Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes</article-title><source>Am Heart J</source><year>2014</year><volume>167</volume><issue>1</issue><fpage>51</fpage><lpage>58.e55</lpage><pub-id pub-id-type="pmid">24332142</pub-id></element-citation></ref><ref id="b11-ppa-11-373"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrank</surname><given-names>WH</given-names></name><name><surname>Hoang</surname><given-names>T</given-names></name><name><surname>Ettner</surname><given-names>SL</given-names></name><etal/></person-group><article-title>The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions</article-title><source>Arch Intern Med</source><year>2006</year><volume>166</volume><issue>3</issue><fpage>332</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">16476874</pub-id></element-citation></ref><ref id="b12-ppa-11-373"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>DC</given-names></name><name><surname>Shrank</surname><given-names>WH</given-names></name><name><surname>Cutler</surname><given-names>D</given-names></name><etal/></person-group><article-title>Patient, physician, and payment predictors of statin adherence</article-title><source>Med Care</source><year>2010</year><volume>48</volume><issue>3</issue><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">19890219</pub-id></element-citation></ref><ref id="b13-ppa-11-373"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolnick</surname><given-names>SJ</given-names></name><name><surname>Pawloski</surname><given-names>PA</given-names></name><name><surname>Hedblom</surname><given-names>BD</given-names></name><name><surname>Asche</surname><given-names>SE</given-names></name><name><surname>Bruzek</surname><given-names>RJ</given-names></name></person-group><article-title>Patient characteristics associated with medication adherence</article-title><source>Clin Med Res</source><year>2013</year><volume>11</volume><issue>2</issue><fpage>54</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">23580788</pub-id></element-citation></ref><ref id="b14-ppa-11-373"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hugtenburg</surname><given-names>JG</given-names></name><name><surname>Timmers</surname><given-names>L</given-names></name><name><surname>Elders</surname><given-names>PJ</given-names></name><name><surname>Vervloet</surname><given-names>M</given-names></name><name><surname>van Dijk</surname><given-names>L</given-names></name></person-group><article-title>Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions</article-title><source>Patient Prefer Adherence</source><year>2013</year><volume>7</volume><fpage>675</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">23874088</pub-id></element-citation></ref><ref id="b15-ppa-11-373"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hoadley</surname><given-names>J</given-names></name><name><surname>Summer</surname><given-names>L</given-names></name><name><surname>Hargrave</surname><given-names>E</given-names></name><name><surname>Cubanski</surname><given-names>J</given-names></name></person-group><source>Medicare Part D Prescription Drug Plans: The Marketplace in 2013 and Key Trends, 2006&#x02013;2013</source><publisher-loc>Menlo Park, CA</publisher-loc><publisher-name>The Henry J. Kaiser Family Foundation</publisher-name><year>2013</year></element-citation></ref><ref id="b16-ppa-11-373"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Academy of Managed Care Pharmacy, American Pharmacists Association</collab></person-group><article-title>Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality</article-title><source>J Am Pharm Assoc (2003)</source><year>2014</year><volume>54</volume><issue>3</issue><fpage>228</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">24770440</pub-id></element-citation></ref><ref id="b17-ppa-11-373"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>The Henry J</collab></person-group><source>Kaiser Family Foundation Key Changes in the Health Reform Law and 2010 Enrollment Data</source><publisher-loc>Menlo Park, CA</publisher-loc><publisher-name>The Henry J. Kaiser Family Foundation</publisher-name><year>2010</year></element-citation></ref><ref id="b18-ppa-11-373"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>BC</given-names></name></person-group><source>How disease burden influences medication patterns for Medicare beneficiaries: implications for policy</source><publisher-name>Commonwealth Fund</publisher-name><year>2008</year></element-citation></ref><ref id="b19-ppa-11-373"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unni</surname><given-names>EJ</given-names></name><name><surname>Farris</surname><given-names>KB</given-names></name></person-group><article-title>Unintentional non-adherence and belief in medicines in older adults</article-title><source>Patient Educ Couns</source><year>2011</year><volume>83</volume><issue>2</issue><fpage>265</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">20542401</pub-id></element-citation></ref><ref id="b20-ppa-11-373"><label>20</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>G</given-names></name><name><surname>Neuman</surname><given-names>T</given-names></name><name><surname>Damico</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><source>Medicare Advantage Plan Star Ratings and Bonus Payments in 2012</source><publisher-loc>Menlo Park, CA</publisher-loc><publisher-name>The Henry J. Kaiser Family Foundation</publisher-name><year>2011</year></element-citation></ref><ref id="b21-ppa-11-373"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>RO</given-names></name><name><surname>Deb</surname><given-names>P</given-names></name><name><surname>Howell</surname><given-names>BL</given-names></name><name><surname>Shrank</surname><given-names>WH</given-names></name></person-group><article-title>Association between Medicare advantage plan star ratings and enrollment</article-title><source>JAMA</source><year>2013</year><volume>309</volume><issue>3</issue><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">23321765</pub-id></element-citation></ref><ref id="b22-ppa-11-373"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MT</given-names></name><name><surname>Bussell</surname><given-names>JK</given-names></name></person-group><article-title>Medication adherence: WHO cares?</article-title><source>Mayo Clin Proc</source><year>2011</year><volume>86</volume><issue>4</issue><fpage>304</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">21389250</pub-id></element-citation></ref><ref id="b23-ppa-11-373"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AlGhurair</surname><given-names>SA</given-names></name><name><surname>Hughes</surname><given-names>CA</given-names></name><name><surname>Simpson</surname><given-names>SH</given-names></name><name><surname>Guirguis</surname><given-names>LM</given-names></name></person-group><article-title>A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the world health organization multidimensional adherence model</article-title><source>J Clin Hypertens (Greenwich)</source><year>2012</year><volume>14</volume><issue>12</issue><fpage>877</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">23205755</pub-id></element-citation></ref><ref id="b24-ppa-11-373"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pringle</surname><given-names>JL</given-names></name><name><surname>Boyer</surname><given-names>A</given-names></name><name><surname>Conklin</surname><given-names>MH</given-names></name><name><surname>McCullough</surname><given-names>JW</given-names></name><name><surname>Aldridge</surname><given-names>A</given-names></name></person-group><article-title>The Pennsylvania Project: pharmacist intervention improved medication adherence and reduced health care costs</article-title><source>Health Aff (Millwood)</source><year>2014</year><volume>33</volume><issue>8</issue><fpage>1444</fpage><lpage>1452</lpage><pub-id pub-id-type="pmid">25092847</pub-id></element-citation></ref><ref id="b25-ppa-11-373"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doshi</surname><given-names>JA</given-names></name><name><surname>Lim</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><etal/></person-group><article-title>A synchronized prescription refill program improved medication adherence</article-title><source>Health Aff (Millwood)</source><year>2016</year><volume>35</volume><issue>8</issue><fpage>1504</fpage><lpage>1512</lpage><pub-id pub-id-type="pmid">27503977</pub-id></element-citation></ref><ref id="b26-ppa-11-373"><label>26</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>S</given-names></name><name><surname>Roemer</surname><given-names>M</given-names></name><name><surname>Stagnitti</surname><given-names>M</given-names></name></person-group><source>Outpatient Prescription Drugs: Data Collection and Editing in the 2011 Medical Expenditure Panel Survey, Methodology Report 29</source><publisher-loc>Rockville, MD</publisher-loc><publisher-name>Agency for Healthcare Research and Quality</publisher-name><year>2014</year></element-citation></ref><ref id="b27-ppa-11-373"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansilal</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>HG</given-names></name><name><surname>Castellano</surname><given-names>J</given-names></name><etal/></person-group><article-title>Assessing the impact of medication adherence on long-term outcomes in patients with diabetes</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>65</volume><issue>8</issue><fpage>789</fpage><lpage>801</lpage></element-citation></ref><ref id="b28-ppa-11-373"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basak</surname><given-names>R</given-names></name><name><surname>McCaffrey Iii</surname><given-names>DJ</given-names></name><name><surname>Bentley</surname><given-names>JP</given-names></name><name><surname>Przybyla</surname><given-names>SM</given-names></name><name><surname>West-Strum</surname><given-names>D</given-names></name><name><surname>Banahan</surname><given-names>BF</given-names></name></person-group><article-title>Adherence to multiple medications prescribed for a chronic disease: a methodological investigation</article-title><source>J Manag Care Spec Pharm</source><year>2014</year><volume>20</volume><issue>8</issue><fpage>815</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">25062075</pub-id></element-citation></ref><ref id="b29-ppa-11-373"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sikka</surname><given-names>R</given-names></name><name><surname>Xia</surname><given-names>F</given-names></name><name><surname>Aubert</surname><given-names>RE</given-names></name></person-group><article-title>Estimating medication persistency using administrative claims data</article-title><source>Am J Manag Care</source><year>2005</year><volume>11</volume><issue>7</issue><fpage>449</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">16044982</pub-id></element-citation></ref><ref id="b30-ppa-11-373"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leslie</surname><given-names>RS</given-names></name><name><surname>Tirado</surname><given-names>B</given-names></name><name><surname>Patel</surname><given-names>BV</given-names></name><name><surname>Rein</surname><given-names>PJ</given-names></name></person-group><article-title>Evaluation of an integrated adherence program aimed to increase Medicare Part D star rating measures</article-title><source>J Manag Care Spec Pharm</source><year>2014</year><volume>20</volume><issue>12</issue><fpage>1193</fpage><lpage>1203</lpage><pub-id pub-id-type="pmid">25443513</pub-id></element-citation></ref><ref id="b31-ppa-11-373"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr-Lopez</surname><given-names>SM</given-names></name><name><surname>Shek</surname><given-names>A</given-names></name><name><surname>Lastimosa</surname><given-names>J</given-names></name><etal/></person-group><article-title>Medication adherence behaviors of Medicare beneficiaries</article-title><source>Patient Prefer Adherence</source><year>2014</year><volume>8</volume><fpage>1277</fpage><lpage>1284</lpage><pub-id pub-id-type="pmid">25258521</pub-id></element-citation></ref><ref id="b32-ppa-11-373"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>TA</given-names></name><name><surname>Dollear</surname><given-names>TJ</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><etal/></person-group><article-title>An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients</article-title><source>Health Aff (Millwood)</source><year>2012</year><volume>31</volume><issue>1</issue><fpage>120</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">22232102</pub-id></element-citation></ref><ref id="b33-ppa-11-373"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couto</surname><given-names>JE</given-names></name><name><surname>Panchal</surname><given-names>JM</given-names></name><name><surname>Lal</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Geographic variation in medication adherence in commercial and Medicare part D populations</article-title><source>J Manag Care Spec Pharm</source><year>2014</year><volume>20</volume><issue>8</issue><fpage>834</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">25062077</pub-id></element-citation></ref><ref id="b34-ppa-11-373"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><article-title>The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials</article-title><source>Stat Med</source><year>2007</year><volume>26</volume><issue>1</issue><fpage>20</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">17072897</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ppa-11-373" position="float"><label>Figure 1</label><caption><p>Cumulative refill rate with 367,631 patients in the intervention group and 367,587 patients in the control group.</p></caption><graphic xlink:href="ppa-11-373Fig1"/></fig><table-wrap id="t1-ppa-11-373" position="float"><label>Table 1</label><caption><p>Baseline patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">Intervention group</th><th valign="top" align="left" rowspan="1" colspan="1">Control group</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of patients</td><td valign="top" align="left" rowspan="1" colspan="1">367,631</td><td valign="top" align="left" rowspan="1" colspan="1">367,587</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Female</td><td valign="top" align="left" rowspan="1" colspan="1">61.0</td><td valign="top" align="left" rowspan="1" colspan="1">60.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean age</td><td valign="top" align="left" rowspan="1" colspan="1">70.4</td><td valign="top" align="left" rowspan="1" colspan="1">70.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"># Of LTR flagged medications (defined at GPI-6 level)</td><td valign="top" align="left" rowspan="1" colspan="1">1.3</td><td valign="top" align="left" rowspan="1" colspan="1">1.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of medications (defined at GPI-6 level) per patient in 6 months</td><td valign="top" align="left" rowspan="1" colspan="1">4.4</td><td valign="top" align="left" rowspan="1" colspan="1">4.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Antihypertensives</td><td valign="top" align="left" rowspan="1" colspan="1">48.8</td><td valign="top" align="left" rowspan="1" colspan="1">48.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Antihyperlipidemics</td><td valign="top" align="left" rowspan="1" colspan="1">47.6</td><td valign="top" align="left" rowspan="1" colspan="1">47.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Beta blockers</td><td valign="top" align="left" rowspan="1" colspan="1">32.4</td><td valign="top" align="left" rowspan="1" colspan="1">32.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Antidepressants</td><td valign="top" align="left" rowspan="1" colspan="1">28.6</td><td valign="top" align="left" rowspan="1" colspan="1">28.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Diuretics</td><td valign="top" align="left" rowspan="1" colspan="1">25.4</td><td valign="top" align="left" rowspan="1" colspan="1">25.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Antidiabetics</td><td valign="top" align="left" rowspan="1" colspan="1">24.4</td><td valign="top" align="left" rowspan="1" colspan="1">24.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Calcium channel blockers</td><td valign="top" align="left" rowspan="1" colspan="1">23.3</td><td valign="top" align="left" rowspan="1" colspan="1">23.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Thyroid agents</td><td valign="top" align="left" rowspan="1" colspan="1">17.7</td><td valign="top" align="left" rowspan="1" colspan="1">17.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Anticonvulsants</td><td valign="top" align="left" rowspan="1" colspan="1">17.6</td><td valign="top" align="left" rowspan="1" colspan="1">17.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">% Antiasthmatic and bronchodilator agents</td><td valign="top" align="left" rowspan="1" colspan="1">12.7</td><td valign="top" align="left" rowspan="1" colspan="1">12.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.4</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ppa-11-373"><p><bold>Notes:</bold> LTR &#x02013; Medications that are late for a refill for at least 3 days. GPI-6 &#x02013; The GPI is a 14-digit code that helps identify pharmaceutical drugs with the same active ingredients, dosage, and strength. The first six digits (GPI-6) of the GPI combine pharmaceutically equivalent drugs together at the therapeutic subclass level.</p></fn><fn id="tfn2-ppa-11-373"><p><bold>Abbreviations:</bold> LTR, late-to-refill; GPI, Generic Product Identifier.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ppa-11-373" position="float"><label>Table 2</label><caption><p>Cumulative refill rate</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1">Days from expected refill date</th><th colspan="2" valign="top" align="left" rowspan="1">Cumulative refill rate (%)
<hr/></th><th rowspan="3" valign="top" align="left" colspan="1">Difference (percentage points)</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Intervention group
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Control group
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">(n=367,631)</th><th valign="top" align="left" rowspan="1" colspan="1">(n=367,587)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">16.5</td><td valign="top" align="left" rowspan="1" colspan="1">12.7</td><td valign="top" align="left" rowspan="1" colspan="1">3.8<xref ref-type="table-fn" rid="tfn4-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">32.8</td><td valign="top" align="left" rowspan="1" colspan="1">26.7</td><td valign="top" align="left" rowspan="1" colspan="1">6.1<xref ref-type="table-fn" rid="tfn4-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">46.1</td><td valign="top" align="left" rowspan="1" colspan="1">41.8</td><td valign="top" align="left" rowspan="1" colspan="1">4.4<xref ref-type="table-fn" rid="tfn4-ppa-11-373">***</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn3-ppa-11-373"><p><bold>Notes:</bold> Chi-square tests used to evaluate whether differences are significant between intervention and control groups.</p></fn><fn id="tfn4-ppa-11-373"><label>***</label><p><italic>P</italic>-value &#x0003c;0.001.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ppa-11-373" position="float"><label>Table 3</label><caption><p>Cumulative refill rate over a 30-day follow-up period by therapeutic class</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1">Therapeutic class<xref ref-type="table-fn" rid="tfn5-ppa-11-373">a</xref></th><th colspan="2" valign="top" align="left" rowspan="1">Intervention group
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Control group
<hr/></th><th rowspan="3" valign="top" align="left" colspan="1">Difference (percentage points)</th></tr><tr><th colspan="2" valign="top" align="left" rowspan="1">(n=367,631)
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">(n=367,587)
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"># Rxs</th><th valign="top" align="left" rowspan="1" colspan="1">Refill rate (%)</th><th valign="top" align="left" rowspan="1" colspan="1"># Rxs</th><th valign="top" align="left" rowspan="1" colspan="1">Refill rate (%)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Antiasthmatic and bronchodilator agents</td><td valign="top" align="left" rowspan="1" colspan="1">19,916</td><td valign="top" align="left" rowspan="1" colspan="1">36.5</td><td valign="top" align="left" rowspan="1" colspan="1">20,017</td><td valign="top" align="left" rowspan="1" colspan="1">31.3</td><td valign="top" align="left" rowspan="1" colspan="1">5.2<xref ref-type="table-fn" rid="tfn6-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antidepressants</td><td valign="top" align="left" rowspan="1" colspan="1">40,520</td><td valign="top" align="left" rowspan="1" colspan="1">46.5</td><td valign="top" align="left" rowspan="1" colspan="1">40,142</td><td valign="top" align="left" rowspan="1" colspan="1">41.9</td><td valign="top" align="left" rowspan="1" colspan="1">4.7<xref ref-type="table-fn" rid="tfn6-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antidiabetics</td><td valign="top" align="left" rowspan="1" colspan="1">34,087</td><td valign="top" align="left" rowspan="1" colspan="1">47.2</td><td valign="top" align="left" rowspan="1" colspan="1">34,102</td><td valign="top" align="left" rowspan="1" colspan="1">42.7</td><td valign="top" align="left" rowspan="1" colspan="1">4.6<xref ref-type="table-fn" rid="tfn6-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antihyperlipidemics</td><td valign="top" align="left" rowspan="1" colspan="1">55,160</td><td valign="top" align="left" rowspan="1" colspan="1">51.8</td><td valign="top" align="left" rowspan="1" colspan="1">55,670</td><td valign="top" align="left" rowspan="1" colspan="1">47.2</td><td valign="top" align="left" rowspan="1" colspan="1">4.6<xref ref-type="table-fn" rid="tfn6-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diuretics</td><td valign="top" align="left" rowspan="1" colspan="1">25,913</td><td valign="top" align="left" rowspan="1" colspan="1">44.6</td><td valign="top" align="left" rowspan="1" colspan="1">26,253</td><td valign="top" align="left" rowspan="1" colspan="1">40.2</td><td valign="top" align="left" rowspan="1" colspan="1">4.4<xref ref-type="table-fn" rid="tfn6-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antihypertensives</td><td valign="top" align="left" rowspan="1" colspan="1">56,423</td><td valign="top" align="left" rowspan="1" colspan="1">51.4</td><td valign="top" align="left" rowspan="1" colspan="1">56,870</td><td valign="top" align="left" rowspan="1" colspan="1">47.3</td><td valign="top" align="left" rowspan="1" colspan="1">4.1<xref ref-type="table-fn" rid="tfn6-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Beta blockers</td><td valign="top" align="left" rowspan="1" colspan="1">32,391</td><td valign="top" align="left" rowspan="1" colspan="1">50.5</td><td valign="top" align="left" rowspan="1" colspan="1">32,363</td><td valign="top" align="left" rowspan="1" colspan="1">46.6</td><td valign="top" align="left" rowspan="1" colspan="1">3.9<xref ref-type="table-fn" rid="tfn6-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Thyroid agents</td><td valign="top" align="left" rowspan="1" colspan="1">18,873</td><td valign="top" align="left" rowspan="1" colspan="1">54.2</td><td valign="top" align="left" rowspan="1" colspan="1">18,649</td><td valign="top" align="left" rowspan="1" colspan="1">50.3</td><td valign="top" align="left" rowspan="1" colspan="1">3.9<xref ref-type="table-fn" rid="tfn6-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Anticonvulsants</td><td valign="top" align="left" rowspan="1" colspan="1">20,920</td><td valign="top" align="left" rowspan="1" colspan="1">43.3</td><td valign="top" align="left" rowspan="1" colspan="1">20,975</td><td valign="top" align="left" rowspan="1" colspan="1">39.5</td><td valign="top" align="left" rowspan="1" colspan="1">3.8<xref ref-type="table-fn" rid="tfn6-ppa-11-373">***</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Calcium channel blockers</td><td valign="top" align="left" rowspan="1" colspan="1">23,501</td><td valign="top" align="left" rowspan="1" colspan="1">51.6</td><td valign="top" align="left" rowspan="1" colspan="1">23,587</td><td valign="top" align="left" rowspan="1" colspan="1">48.2</td><td valign="top" align="left" rowspan="1" colspan="1">3.4<xref ref-type="table-fn" rid="tfn6-ppa-11-373">***</xref></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn5-ppa-11-373"><label>a</label><p>Top 10 therapeutic classes by volume. Chi-square tests used to evaluate whether differences are significant between intervention and control group.</p></fn><fn id="tfn6-ppa-11-373"><label>***</label><p><italic>P</italic>-value &#x0003c;0.001.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ppa-11-373" position="float"><label>Table 4</label><caption><p>PDC comparison</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="left" rowspan="1" colspan="1">Number of Rxs</th><th valign="top" align="left" rowspan="1" colspan="1">Mean PDC (%)</th><th valign="top" align="left" rowspan="1" colspan="1">SD (%)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervention group (n=367,631)</td><td valign="top" align="left" rowspan="1" colspan="1">466,721</td><td valign="top" align="left" rowspan="1" colspan="1">56.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control group (n=367,587)</td><td valign="top" align="left" rowspan="1" colspan="1">467,448</td><td valign="top" align="left" rowspan="1" colspan="1">55.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Difference (percentage points)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.9<xref ref-type="table-fn" rid="tfn8-ppa-11-373">***</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn7-ppa-11-373"><p><bold>Notes:</bold> PDC &#x02013; proportion of days covered over a 365-day period from index fill.</p></fn><fn id="tfn8-ppa-11-373"><label>***</label><p><italic>P</italic>-value &#x0003c;0.001.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-ppa-11-373" position="float"><label>Table 5</label><caption><p>Adherence level comparison</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Group</th><th valign="top" align="left" rowspan="1" colspan="1">% nonadherent
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">% partially adherent
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">% adherent
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">(PDC &#x0003c;50%)</th><th valign="top" align="left" rowspan="1" colspan="1">(50%&#x02264; PDC &#x0003c;80%)</th><th valign="top" align="left" rowspan="1" colspan="1">(PDC &#x02265;80%)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervention group (n=367,631)</td><td valign="top" align="left" rowspan="1" colspan="1">45.1</td><td valign="top" align="left" rowspan="1" colspan="1">20.4</td><td valign="top" align="left" rowspan="1" colspan="1">34.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control group (n=367,587)</td><td valign="top" align="left" rowspan="1" colspan="1">46.2</td><td valign="top" align="left" rowspan="1" colspan="1">20.3</td><td valign="top" align="left" rowspan="1" colspan="1">33.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Difference (percentage points)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.1<xref ref-type="table-fn" rid="tfn10-ppa-11-373">***</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.1</td><td valign="top" align="left" rowspan="1" colspan="1">1.0<xref ref-type="table-fn" rid="tfn10-ppa-11-373">***</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn9-ppa-11-373"><p><bold>Notes:</bold> Chi-square tests used to evaluate whether differences are significant between intervention and control groups.</p></fn><fn id="tfn10-ppa-11-373"><label>***</label><p><italic>P</italic>-value &#x0003c;0.001.</p></fn><fn id="tfn11-ppa-11-373"><p><bold>Abbreviation:</bold> PDC, proportion of days covered.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6-ppa-11-373" position="float"><label>Table 6</label><caption><p>Persistence comparison</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="left" rowspan="1" colspan="1"># Rxs</th><th valign="top" align="left" rowspan="1" colspan="1">Mean persistence (days)</th><th valign="top" align="left" rowspan="1" colspan="1">SD (days)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Intervention group (n=367,631)</td><td valign="top" align="left" rowspan="1" colspan="1">466,721</td><td valign="top" align="left" rowspan="1" colspan="1">182.2</td><td valign="top" align="left" rowspan="1" colspan="1">99.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control group (n=367,587)</td><td valign="top" align="left" rowspan="1" colspan="1">467,448</td><td valign="top" align="left" rowspan="1" colspan="1">180.0</td><td valign="top" align="left" rowspan="1" colspan="1">99.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Difference (days)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">2.2<xref ref-type="table-fn" rid="tfn13-ppa-11-373">***</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn12-ppa-11-373"><p><bold>Notes:</bold> Persistence is measured as the duration of days from initiation to discontinuation of maintenance medication over a 270-day period.</p></fn><fn id="tfn13-ppa-11-373"><label>***</label><p><italic>P</italic>-value &#x0003c;0.001).</p></fn></table-wrap-foot></table-wrap></floats-group></article>